Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

The company reported a 9.5% fall in its consolidated net profit after tax to 13.42 billion rupees ($159.6 million) for the quarter ended Sept. 30, missing analysts' estimate of 14.01 billion rupees, ...

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

Last month, the US Food and Drug Administration (FDA) approved three new drugs, as well as a potentially practice-changing ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

Clairity, Inc., a pioneer in AI-based predictive tools for breast cancer, is pleased to announce the appointment of Jeffrey R. Luber, JD, MBA, as President, Chief Executive Officer and Director. Luber ...